启迪药业(000590) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥87,878,389.50, representing a 48.49% increase compared to ¥59,179,800.24 in the same period last year[7]. - Net profit attributable to shareholders was ¥10,787,950.32, a significant increase of 97.67% from ¥5,457,422.00 year-on-year[7]. - The net profit after deducting non-recurring gains and losses reached ¥10,594,514.03, up 192.90% from ¥3,617,144.06 in the previous year[7]. - The basic earnings per share increased to ¥0.0450, reflecting a growth of 97.37% compared to ¥0.0228 in the same period last year[7]. - The weighted average return on equity improved to 1.84%, up from 0.93% year-on-year, indicating better profitability[7]. - Total operating revenue for the current period reached ¥87,878,389.50, a significant increase from ¥59,179,800.24 in the previous period, representing a growth of approximately 48.5%[37]. - Total operating costs amounted to ¥75,632,263.24, up from ¥54,657,253.68, indicating an increase of about 38.3%[37]. - Net profit for the current period was ¥10,787,950.32, compared to ¥5,457,422.00 in the previous period, reflecting an increase of approximately 97.5%[39]. - The operating profit for the current period was ¥12,460,455.78, which is an increase from ¥7,019,672.29, showing a growth of around 77.5%[39]. - The total profit for the current period was ¥12,471,622.81, up from ¥6,957,422.00, which is an increase of approximately 79.5%[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥811,386,713.13, a slight decrease of 0.64% from ¥816,598,767.73 at the end of the previous year[7]. - The net assets attributable to shareholders increased to ¥590,506,709.50, marking a 1.86% rise from ¥579,718,759.18 at the end of the last year[7]. - Total liabilities decreased from CNY 236,880,008.55 to CNY 220,880,003.63, a decline of about 6.77%[30]. - Current liabilities decreased from CNY 141,022,884.86 to CNY 125,228,990.89, a reduction of about 11.19%[30]. - Non-current liabilities slightly decreased from CNY 95,857,123.69 to CNY 95,651,012.74, a decrease of approximately 0.22%[30]. - Owner's equity increased from CNY 579,718,759.18 to CNY 590,506,709.50, an increase of approximately 1.36%[31]. - The company’s total liabilities and owner's equity totaled CNY 811,386,713.13, consistent with total assets[31]. Cash Flow - The company reported a net cash flow from operating activities of -¥5,179,641.84, an improvement of 85.88% compared to -¥36,691,589.68 in the same period last year[7]. - Cash flow from operating activities netted ¥31,511,947.84, an increase of 85.88% attributed to higher cash receipts from sales[14]. - The cash flow from operating activities was ¥70,722,761.54, compared to ¥51,694,680.68 in the previous period, indicating a growth of about 36.8%[46]. - Total cash inflow from operating activities was 72,927,686.74 CNY, while cash outflow was 78,107,328.58 CNY, resulting in a net cash flow deficit[47]. - The cash flow from investment activities was -2,069,109.40 CNY, compared to -3,635,398.28 CNY in the previous period, showing a decrease in cash outflow[48]. - Cash flow from financing activities resulted in a net outflow of -8,433,016.66 CNY, significantly higher than -326,672.67 CNY in the previous period[48]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,286[10]. - The largest shareholder, Tsinghua Tongfang Co., Ltd., held 29.41% of the shares, while the second-largest shareholder, the Hengyang Municipal Government, held 15.84%[10]. Expenses - Research and development expenses surged by 107.73% to ¥1,455,131.65, reflecting increased personnel and investment in R&D[14]. - The company reported a tax expense of ¥1,683,672.49 for the current period, compared to ¥1,500,000.00 in the previous period, reflecting an increase of about 12.2%[39]. - The company reported a 61.41% increase in sales expenses to ¥5,668,238.75, correlating with the rise in operating revenue[14]. - Research and development expenses increased to ¥2,805,792.20 from ¥1,350,660.55, marking a rise of approximately 107%[37].